Efficacy And Safety Of Ashwagandha Root Extract In Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial
Notes for this study:
||(nmol/L). Placebo: before 91.80 (13.45), after 95.84 (30.82). Ashwagandha: before 93.53 (12.88), after 111.84 (14.01)
|Number of Subjects
||18-29, 30-44, 45-64
In a randomized, double-blind, placebo-controlled trial, 50 participants with subclinical hypothyroidism were assigned to take 600 mg of a 100% aqueous extract of ashwagandha (5% withanolides) or placebo daily for 8 weeks.
There was a notable, statistically significant increase in T3 and T4 and a notable reduction in TGH in the ashwagandha group compared with the placebo group.
There was no notable difference between groups for adverse events.